Feature | Heart Valve Technology | February 15, 2018

Edwards Lifesciences Self Expanding TAVR Valve Gains European Approval

Edwards Lifesciences Centera self expanding transcatheter (TAVR) valve has been approved with CE mark for use in Europe.

February 15, 2018 — Edwards Lifesciences Corp. has received European CE mark clearance for its self-expanding Centera transcatheter aortic valve replacement (TAVR) device for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery. 

The Centera valve is repositionable and retrievable and can be delivered through a low-profile, 14-French, motorized delivery system. It is uniquely packaged with the valve fully pre-attached to the delivery system, which facilitates simple and rapid device preparation.

"With the Edwards Centera valve, European clinicians and their patients may now benefit from a self-expanding TAVR option that has demonstrated exceptional clinical safety and performance outcomes in the high surgical risk population," said Didier Tchétché, M.D., of Clinique Pasteur in Toulouse, France. "Enhanced design features of the Centera valve, including a motorized handle that enables stable valve deployment, allow for a simpler procedure with compelling outcomes."

European certification of the Centera valve was based on the CENTERA-EU Trial, which enrolled 203 high-risk patients at 23 centers in Europe, Australia and New Zealand. Study results presented at EuroPCR 2017 demonstrated high survival rates (99 percent) and low rates of disabling stroke (2.5 percent) and new permanent pacemaker (4.9 percent) at 30 days. In addition, there was a low 0.6 percent rate of moderate paravalvular leak among patients, and zero incidents of severe paravalvular leak. All patients in the study were treated via the transfemoral access route with the majority under conscious sedation.

Read the article about the CENTERA-EU Trial, “Edwards' Self-Expanding Transcatheter Heart Valve Demonstrates Excellent Early Patient Outcomes.”

Edwards was the first to market in the United States with the an aortic transcatheter valve in 2011 when the U.S. Food and Drug Administration (FDA) cleared the the first Sapien transcatheter heart valve (THV). The device uses a balloon-expandable stent frame that only allows for one attempt at positioning the valve. The second TAVR valve to be cleared by the FDA was Medtronic's CoreValve, which uses a self-expanding frame to seat the valve. This allows for repositioning prior to final release or the valve. The repositionability of the CoreValve offers several advantages over the Sapien, which in part led to the development of the Centera valve, which is both is repositionable and retrievable.

The Centera valve is not approved for commercial sale in the U.S.

Tchétché is a consultant to Edwards Lifesciences.

For more information: www.edwards.com

Reference:

1. Reichenspurner H, Schaefer A, Schäfer U, Tchétché D, et al. Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. J Am Coll Cardiol. 2017 Dec 26;70(25):3127-3136. doi: 10.1016/j.jacc.2017.10.060.


Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now